Q-omics provides the consensus-scored MIR4448 profile across patient tissues and cancer cell-line models. MIR4448 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MIR4448 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MIR4448 RNA expression shows 6,083 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, KIRC, and STAD as cancer lineages where MIR4448 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4448 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4448 survival associations across molecular data types. MIR4448 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4448 RNA expression–survival associations across cancer types. High MIR4448 expression shows unfavorable associations in LUAD, KIRC, PCPG, GBM and COAD, but favorable associations in SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MIR4448 RNA expression.
This table summarizes MIR4448 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4448. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4448 shows lower tumor expression in KIRC. The KIRC box plot shows higher MIR4448 RNA expression in normal versus tumor tissue (log2 FC = −0.103, t-test p = .010).
This table shows molecular features associated with MIR4448 in patient tissues and cancer cell lines. In patient samples, MIR4448 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
